Eyepoint Pharmaceuticals CEO featured for advances in OCT retina imaging tool

Eyepoint Pharmaceuticals CEO featured for advances in OCT retina imaging tool
Eyepoint spotlights OCT technology

Eyepoint Pharmaceuticals president and CEO Jay S. Duker, M.D., has been recognized in Retina Today’s ‘Then and Now’ spotlight for his perspective on the progress of optical coherence tomography (OCT), a non-invasive retina imaging technology that has reshaped eye care over the past two decades.

Duker outlines how OCT advancements have elevated clinical practice and improved patient outcomes in ophthalmology, noting its pivotal role in diagnosing and managing retinal diseases.

Eyepoint Pharmaceuticals has expanded research efforts at its Northbridge facility to develop new therapies targeting retinal diseases, according to a previous update on its innovation pipeline. Earlier this year, the company reported its Q1 2026 results and provided details on progress in a pivotal Phase 3 clinical trial for a key retinal treatment. The company continues to focus on advancing technologies and treatments for serious retinal conditions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.